视网膜层萎缩与复发型多发性硬化临床及影像进展的关联
本研究基于前瞻性观察队列,纳入210例复发型多发性硬化患者,探讨视网膜层萎缩与不依赖复发和MRI活动的进展(PIRMA)的关系。多变量混合效应模型显示,PIRMA与GCIPL和pRNFL更显著的变薄独立相关,提示视网膜萎缩可作为独立于急性炎症的神经轴索退变生物标志物。
要点
- PIRMA见于13.3%患者,占所有残疾累积的41.8%,占PIRA的54.1%。
- PIRMA与GCIPL年变薄0.72%、pRNFL年变薄1.05%显著相关。
- 视网膜萎缩或可反映独立于急性局灶炎症的MS神经退变。
核心结论
- 视网膜层萎缩与PIRMA显著相关,支持其作为MS相关神经轴索退变生物标志物的潜力。
研究设计与样本
- 前瞻性观察研究,纳入210例复发型多发性硬化患者,中位观察2.3年(范围1-5.9年)。
- OCT扫描于DMT启动后3-6个月(重基线)及至少12个月后随访时进行。
主要发现
- PIRMA见于28例(13.3%总体,41.8%的残疾累积,54.1%的PIRA),PIRA见于50例(23.8%总体,77.2%的残疾累积)。
- PIRMA vs 无PIRMA与GCIPL年变薄0.72%(95%CI 0.50-0.82,p<0.001)相关。
- PIRMA vs 无PIRMA与pRNFL年变薄1.05%(95%CI 0.89-1.18,p<0.001)相关。
关键数值与推荐
- 残疾累积采用复合指标:EDSS、T25FW、9-HPT或SDMT任一恶化,采用移动基线,6个月确认间隔。
- PIRA定义为移动基线至确认期间无复发的残疾累积;PIRMA定义为影像学静默的PIRA。
- 多变量混合效应线性回归模型校正年龄、性别、病程、重基线GCIPL/pRNFL及中等 vs 高效DMT。
临床怎么用
- OCT测量的GCIPL和pRNFL变薄速率或有助于识别独立于急性炎症的MS进展风险。
- 对RMS患者可考虑系列OCT监测,辅助评估神经退变进程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Progression independent of relapse activity (PIRA) is the main driver of disability accumulation in relapsing multiple sclerosis (RMS). Retinal layer atrophy measured by optical coherence tomography (OCT) reflects neuroaxonal damage and is associated with PIRA. However, it remains unclear whether this association is driven by subclinical inflammatory activity or reflects true progression independent of acute inflammation. Here, we aimed to investigate the relationship between retinal layer atrophy and progression independent of relapse and MRI activity (PIRMA) to clarify the impact of subclinical inflammatory activity. METHODS: From an ongoing prospective observational study, patients with RMS meeting the following criteria were included: an OCT scan conducted 3-6 months after disease-modifying treatment (DMT) initiation (rebaseline) and at least one follow-up OCT after ≥12 months. Disability accrual was defined as a composite measure comprising worsening in either Expanded Disability Status, Timed 25-Foot Walk Test, 9-Hole Peg Test, or Symbol Digit Modalities Test using a roving baseline with a 6-month confirmation interval. PIRA was defined as disability accrual without relapse between roving baseline and confirmation. PIRMA was defined as PIRA that remained radiologically silent. We evaluated associations between PIRMA and thinning of the peripapillary retinal nerve fiber layer (pRNFL) and the macular ganglion cell plus inner plexiform layer (GCIPL) using multivariable mixed-effects linear regression models adjusted for relevant covariables (age, sex, disease duration, GCIPL/pRNFL at rebaseline, and moderate vs high-efficacy DMT). RESULTS: A total of 210 patients with RMS (mean age 30.5 years, SD 7.9; 74.1% female) were analyzed over a median observation period of 2.3 years (range 1-5.9 years). PIRMA was observed in 28 (13.3% overall, 41.8% of all disability accruals, 54.1% of PIRA) patients, while PIRA was encountered in 50 (23.8% overall, 77.2% of all disability accruals). Multivariable models revealed that PIRMA (vs no PIRMA) was associated with significantly more pronounced thinning of both GCIPL (0.72% per year, 95% CI 0.50-0.82, p < 0.001) and pRNFL (1.05% per year, 95% CI 0.89-1.18, p < 0.001). DISCUSSION: Our findings indicate that retinal atrophy is significantly linked with PIRMA, reinforcing its potential as a biomarker of MS-related neuroaxonal degeneration that occurs independently of acute focal inflammation.
引用
- Bsteh G, Hegen H, Krajnc N, et al. Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis. Neurology. 2025. PMID: 41021870. doi:10.1212/WNL.0000000000214069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。